Skip to content

Effects of synbiotic supplementation on intestinal microbiota , antioxidant status and short chain fatty acids among pediatric obesity : A Randomized clinical trial

Effects of synbiotic supplementation on intestinal microbiota , antioxidant status and short chain fatty acids among pediatric obesity : A Randomized clinical trial

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20240321005
Enrollment
60
Registered
2024-03-21
Start date
2024-07-31
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The modulation of gut microbiota, metabolites, and short-chain fatty acids in obese Thai children while receiving synbiotics. obesity, synbiotic, prebiotic, probiotic, short chain fatty acids, metabolites, gut microbiota

Interventions

The synbiotic product consists of a combination of prebiotics and probiotics. The prebiotic component comprises of inulin, while the probiotics include Bifidobacterium longum B69, Bifidobacterium adol
Experimental Other,Placebo Comparator Other
Synbiotic,Placebo

Sponsors

Faculty of Medicine, Chulalongkorn University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
7 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. Age 7 to 18 years 2. BMI > median + 2SDs (WHO reference) 3. No history of pre-/pro-/ synbiotic supplementation or antibiotics use at least 4 weeks prior to participation.

Exclusion criteria

Exclusion criteria: 1. Cow's milk protein allergy 2. Syndromic obesity 3. Endocrine causes of obesity (e.g. hypothyroidism, growth hormone deficiency) 4. Use of drugs that influence apetite or body weight (e.g. corticosteroids) 5. Attending other concurrent weight reduction programs

Design outcomes

Primary

MeasureTime frame
Short chain fatty acids At the time of enrollment and three months thereafter Measure in stool sample,Gut microbiota At the time of enrollment and three months thereafter Measure in stool sample

Secondary

MeasureTime frame
Metabolites profile At the time of enrollment and three months thereafter Measure in serum: iNOS, IL-1B, MCP-1, LPS, LBP, MDA, TGF-B, FIZZ, Arginase, IL-10 ,Metabolic profiles At the time of enrollment and three months thereafter Measure in serum lipid profile, fasting blood sugar levels, and insulin levels

Countries

Thailand

Contacts

Public ContactChonnikant Visuthranukul

Faculty of Medicine, Chulalongkorn University

chonnikant.v@chula.ac.th66818177284

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026